Korea Q1 Roundup: Overseas Sales, COVID Prove Positive In Mixed Results
SK Bioscience Files For Vaccine
Among recent highlights, SK Bioscience files for approval of recombinant protein COVID-19 vaccine GBP510, Hanmi Pharmaceutical’s Chinese subsidiary continues to report strong earnings, led by cold drug sales, while Yuhan’s novel peptide drug candidate for degenerative disc disease is set to move into a Phase III trial in the US.
You may also be interested in...
Spine Takes Yuhan’s Peptide Into US Phase III For High-Need DDD
Major Korean firm Yuhan is seeing progress across multiple novel drug candidates licensed out to global partners, with two now entering pivotal trials. An innovative therapy for degenerative disc disease licensed to Spine BioPharma has received an FDA nod for a Phase III program and may change the standard of care for chronic low back pain patients.
Next Big Step: SK Bioscience Gears Up For Endemic COVID, Next Pandemic
With its COVID-19 vaccine development project nearing the finish line, SK Bioscience unveils an ambitious growth strategy which includes mergers and acquisitions and diversification into the cell and gene therapy sector.
Looking Beyond CNS, SK Biopharm Begins First US Oncology Trial
The CNS-focused SK Group affiliate has set out ambitious growth plans for this year and is moving forward with a diversification into oncology and other areas, beginning its first US cancer trials in brain tumors and cancers with brain metastasis.